 Platelet Aggregation Inhibitors
"Platelet Aggregation Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
| Descriptor ID |
D010975
|
| MeSH Number(s) |
D27.505.954.502.780
|
| Concept/Terms |
Platelet Aggregation Inhibitors- Platelet Aggregation Inhibitors
- Aggregation Inhibitors, Platelet
- Inhibitors, Platelet Aggregation
- Blood Platelet Antiaggregants
- Antiaggregants, Blood Platelet
- Platelet Antiaggregants
- Antiaggregants, Platelet
- Blood Platelet Aggregation Inhibitors
Antiplatelet Agents- Antiplatelet Agents
- Agents, Antiplatelet
- Antiplatelet Drugs
- Drugs, Antiplatelet
Platelet Antagonists- Platelet Antagonists
- Antagonists, Platelet
- Blood Platelet Antagonists
- Antagonists, Blood Platelet
|
Below are MeSH descriptors whose meaning is more general than "Platelet Aggregation Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Platelet Aggregation Inhibitors".
This graph shows the total number of publications written about "Platelet Aggregation Inhibitors" by people in this website by year, and whether "Platelet Aggregation Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 0 | 2 | | 1997 | 2 | 0 | 2 | | 1998 | 4 | 2 | 6 | | 1999 | 3 | 0 | 3 | | 2000 | 3 | 0 | 3 | | 2001 | 1 | 2 | 3 | | 2002 | 3 | 1 | 4 | | 2003 | 1 | 1 | 2 | | 2004 | 1 | 1 | 2 | | 2005 | 1 | 4 | 5 | | 2006 | 2 | 2 | 4 | | 2007 | 2 | 0 | 2 | | 2008 | 7 | 0 | 7 | | 2009 | 7 | 2 | 9 | | 2010 | 4 | 0 | 4 | | 2011 | 3 | 6 | 9 | | 2012 | 4 | 3 | 7 | | 2013 | 11 | 0 | 11 | | 2014 | 8 | 6 | 14 | | 2015 | 11 | 11 | 22 | | 2016 | 20 | 9 | 29 | | 2017 | 10 | 6 | 16 | | 2018 | 14 | 12 | 26 | | 2019 | 7 | 9 | 16 | | 2020 | 23 | 11 | 34 | | 2021 | 6 | 13 | 19 | | 2022 | 4 | 12 | 16 | | 2023 | 3 | 11 | 14 | | 2024 | 1 | 1 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "Platelet Aggregation Inhibitors" by people in Profiles.
-
Aquilante CL, Trinkley KE, Lee YM, Crooks KR, Hearst EC, Heckman SM, Hess KW, Kudron EL, Martin JL, Swartz CT, Kao DP. Implementation of clopidogrel pharmacogenetic clinical decision support for a preemptive return of results program. Am J Health Syst Pharm. 2024 Jun 11; 81(12):555-562.
-
Orjuela KD, Leppert MH, Carroll JD. Navigating the Gray: The Complex Story of PFO Closure Utilization. Circ Cardiovasc Qual Outcomes. 2024 01; 17(1):e010581.
-
Parodi G, Dossi F, Raccis M, Talanas G, Mura E, Siciliano R, Guarino S, Marini A, Franca P, Saba PS, Sanna GD, Canonico ME. Platelet inhibition with orodispersible ticagrelor in acute coronary syndromes according to morphine use: the TASTER study final results. Eur Heart J Cardiovasc Pharmacother. 2023 Dec 14; 9(8):692-700.
-
Bonaca MP, Les?n E, Giannitsis E, Hedberg J, Jernberg T, Lambrelli D, Duong M, Maggioni AP, Ariza-Sol? A, Ten Berg J, Storey RF. Characteristics and outcomes in patients with a prior myocardial infarction treated with extended dual antiplatelet therapy with ticagrelor 60 mg: findings from ALETHEIA, a multi-country observational study. Eur Heart J Cardiovasc Pharmacother. 2023 Dec 14; 9(8):701-708.
-
Rymer J, Anand SS, Sebastian Debus E, Haskell LP, Hess CN, Jones WS, Muehlhofer E, Berkowitz SD, Bauersachs RM, Bonaca MP, Patel MR. Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD. Circulation. 2023 12 12; 148(24):1919-1928.
-
Denorme F, Armstrong ND, Stoller ML, Portier I, Tugolukova EA, Tanner RM, Montenont E, Bhatlekar S, Cody M, Rustad JL, Ajanel A, Tolley ND, Murray DC, Boyle JL, Nieman MT, McKenzie SE, Yost CC, Lange LA, Cushman M, Irvin MR, Bray PF, Campbell RA. The predominant PAR4 variant in individuals of African ancestry worsens murine and human stroke outcomes. J Clin Invest. 2023 09 15; 133(18).
-
Vranic JE, Harker P, Stapleton CJ, Regenhardt RW, Dmytriw AA, Doron OM, Alotaibi NM, Leslie-Mazwi TM, Gupta R, Berglar IK, Tan CO, Koch MJ, Raymond SB, Mascitelli JR, Patterson TT, Seinfeld J, White A, Case D, Roark C, Gandhi CD, Al-Mufti F, Cooper J, Matouk C, Sujijantarat N, Devia DA, Ocampo-Navia MI, Villamizar-Torres DE, Puentes JC, Patel AB. The Impact of Dual Antiplatelet Therapy Duration on Unruptured Aneurysm Occlusion After Flow Diversion: A Multicenter Study. J Comput Assist Tomogr. 2023 Sep-Oct 01; 47(5):753-758.
-
Aijaz B, Glorioso TJ, Butala N, Waldo SW. Temporal trends and hospital variation in the use of P2Y12 inhibitors among patients undergoing percutaneous coronary intervention: Insights from the VA CART program. Catheter Cardiovasc Interv. 2023 09; 102(3):503-504.
-
Faridi KF, Strom JB, Kundi H, Butala NM, Curtis JP, Gao Q, Song Y, Zheng L, Tamez H, Shen C, Secemsky EA, Yeh RW. Association Between Claims-Defined Frailty and Outcomes Following 30 Versus 12 Months of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention: Findings From the EXTEND-DAPT Study. J Am Heart Assoc. 2023 07 18; 12(14):e029588.
-
Brioso XB, Bolt M, Sammel MD, McKenney K. Abnormal uterine bleeding in anticoagulated patients by drug class: outcomes and management. Am J Obstet Gynecol. 2023 09; 229(3):318.e1-318.e14.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|